| Cat.No. | Name | Information |
|---|---|---|
| M8959 | BMS-1 (PD-1/PD-L1 inhibitor 1, PD1-PDL1-IN1) | BMS-1 (PD-1/PD-L1 inhibitor 1, PD1-PDL1-IN1) is an inhibitor of PD-1/PD-L1 protein/protein interaction with an IC50 of 6 to 100 nM. |
| M6101 | Atezolizumab | Atezolizumab (atezolizumab) is a humanized anti-PD-L1 monoclonal antibody that inhibits PD-L1 signaling with PD-1 and B7-1 and restores tumor-specific T-cell immunity. However, it does not affect the interaction of PD-L2 with PD-1. Atezolizumab reacts with murine PD-L1 (for human and non-humanized mice). |
| M3813 | Avelumab (MSB0010718C) | Avelumab is a whole monoclonal antibody of isotype IgG1 that binds to the programmed death-ligand 1 (PD-L1) and therefore inhibits binding to its receptor programmed cell death 1 (PD-1). Avelumab recognizes murine PD-L1 |
| M6100 | Nivolumab | Nivolumab (nabumab) is a fully humanized IgG4 monoclonal antibody against PD-1. It has immune checkpoint inhibitory activity and antitumor activity; MW: 143.597 KD.(for human-derived mice). |
| M6102 | Pembrolizumab | Pembrolizumab (pembrolizumab) is a humanized anti-PD-1 monoclonal antibody that blocks the interaction between PD-1 and its ligands PD-L1 and PD-L2. It has immune checkpoint inhibitory activity and antitumor activity. MW: 146.286 KD.(Pembrolizumab does not recognize murine PD-1 protein, humanized mice or mice expressing human PD-1 gene are required). |
| M5979 | Sulfamethoxypyridazine | Sulfamethoxypyridazine is a long-acting sulfonamide for treatment of Dermatitis herpetiformis. |
| M5144 | BMS202 | Bms-202 is an effective non-peptide PD-1/PD-L complex inhibitor with IC50 of 18 nM and KD of 8 μM. Bms-202 directly binds to PD-L1 and blocks the human PD-1/PD-L interaction. Bms-202 has antitumor activity. |
| M4556 | Fraxinellone | Fraxinellone was isolated from the root bark of the brassica family Dictamnus dasycarpus. Fraxinellone is a PD-L1 inhibitor that inhibits HIF-1α synthesis without affecting HIF-1α degradation. Fraxinellone has potential for cancer immunity by targeting PD-L1. |
| M4093 | Panaxadiol | Panaxadiol exists in ginseng root and has neuroprotective and anti-tumor functions. Panaxadiol inhibits the expression of programmed cell death ligand-1 (PD-L1) and tumor proliferation. |
| M58107 | PD-1/PD-L1-IN-9 | PD-1/PD-L1-IN-9 is a potent and orally active inhibitor of PD-1/PD-L1 interaction, with an IC50 of 3.8 nM. PD-1/PD-L1-IN-9 can enhance the killing activity of tumor cells by immune cells. PD-1/PD-L1-IN-9 also exhibits significant in vivo antitumor activity in a CT26 mouse model. |
| M56388 | NSC622608 | NSC622608 is a V-domain Ig suppressor of T-cell activation (VISTA) ligand with an IC50 value of 4.8 μM. |
| M56387 | PD-L1-IN-1 | PD-L1-IN-1 is a potent PD-L1 inhibitor with an IC50 of 115 nM. |
| M55253 | SL-279252 | SL-279252 (PD1-Fc-OX40L) is a hexameric, bi-functional fusion protein with an ECD of PD-1 (70 pM affinity to PD-L1) linked to the ECD of OX40L (324 pM affinity for OX40) through an Fc linker. SL-279252 exhibited linear PK at doses up to 3.0 mg/kg, and a greater than proportional increase in AUC was observed at 6.0 mg/kg suggesting potential receptor saturation. The preliminary half-life is approximately 23 hours. |
| M55035 | Rosnilimab | Rosnilimab is a novel PD-1 checkpoint agonist antibody that reduces overactive T cell inflammation. Rosnilimab optimizes PD-1+ T cell inhibitory signaling by enabling tight immune synapse formation. Rosnilimab restores immune balance bringing T cell composition to a less activated state. |
| M54553 | Erfonrilimab | Erfonrilimab is a humanized single-domain bispecific antibody-Fc fusion protein (VH-VH-h-CH2-CH3 dimer) targeting the immune checkpoints PD-L1 and CTLA-4. |
| M54548 | Benmelstobart | Benmelstobart is an anti-PD-L1 humanized IgG1ҡ monoclonal antibody that can be used for tumor-related studies. |
| M54428 | Human PD-L1 inhibitor II | Human PD-L1 inhibitor II is a potent PD-L1 inhibitor with anti-cancer activity. |
| M54299 | Human PD-L1 inhibitor I | Human PD-L1 inhibitor I is a hPD-1 peptide ligand, with a KD of 3.39 μM. |
| M54269 | Human PD-L1 inhibitor V | Human PD-L1 inhibitor V, a human PD-1 protein binding peptide with a Kd value of 3.32 μM. |
| M54045 | Human PD-L1 inhibitor IV | Human PD-L1 inhibitor IV, a polypeptide, is a competitive human PD-1 protein inhibitor with a Kd value of 1.38 μM. |
| M52843 | Human PD-L1 inhibitor III | Human PD-L1 inhibitor III is a human PD-L1 inhibitor. |
| M52842 | [D-Leu-4]-OB3 | [D-Leu-4]-OB3 inhibits expressions of pro-inflammatory, proliferative and metastatic genes and PD-L1 expression. |
| M52841 | (D)-PPA 1 | (D)-PPA 1 is a hydrolysisresistant d-peptide antagonist. |
| M52840 | Human membrane-bound PD-L1 polypeptide | Human membrane-bound PD-L1 polypeptide can be used as an antigen to induce PD-L1 antibody production. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
